Abstract
β-Arrestin function has largely been investigated in cell culture-based systems. Here we describe methods to investigate β-arrestin2 signaling in vivo by developing novel mouse models and viral methods to overexpress β-arrestin2 in the mouse brain. The methods and concepts described here are in the context of Parkinson’s disease (PD) and developing automated in vivo drug screening platforms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22(12):5042–5054
Porras G, Berthet A, Dehay B, Li Q, Ladepeche L, Normand E, Dovero S, Martinez A, Doudnikoff E, Martin-Negrier ML, Chuan Q, Bloch B, Choquet D, Boue-Grabot E, Groc L, Bezard E (2012) PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest 122(11):3977–3989. https://doi.org/10.1172/JCI5942659426
Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG (2015) Targeting beta-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease. Proc Natl Acad Sci U S A 112(19):E2517–E2526. https://doi.org/10.1073/pnas.15027401121502740112
Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, Gainetdinov RR (2005) Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3(8):e271. doi:05-PLBI-RA-0272R3. https://doi.org/10.1371/journal.pbio.0030271
Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15(1):120–132. doi:1843
Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16(1):110–123. https://doi.org/10.1016/j.nbd.2004.01.007S0969996104000178
Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408(6813):720–723. https://doi.org/10.1038/35047086
Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194(1):66–75
Acknowledgments
I would like to thank the Michael J. Fox Foundation (grant #11764) for their support in this project. I would also like to thank Dr. Marc Caron, in whose lab this work was conducted.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Urs, N.M. (2019). Methods to Investigate the Role of β-Arrestin Signaling in Parkinson’s Disease. In: Scott, M., Laporte, S. (eds) Beta-Arrestins. Methods in Molecular Biology, vol 1957. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9158-7_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9158-7_24
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9157-0
Online ISBN: 978-1-4939-9158-7
eBook Packages: Springer Protocols